| 引用本文:马成龙，茅卫东，刘少平，钱文军，闫帅，沈冬.正元胶囊联合程序性死亡受体1抗体治疗晚期肺癌的临床观察[J].世界中医药,2020,(22):. |
|
| 正元胶囊联合程序性死亡受体1抗体治疗晚期肺癌的临床观察 |
| Clinical Observation of Zhengyuan Capsule Combined with Programmed Death Receptor 1 Antibody in the Treatment of Advanced Lung Cancer |
| 投稿时间：2020-09-22 |
| DOI：10.3969/j.issn.1673-7202.2020.22.015 |
| 中文关键词: 正元胶囊 程序性死亡受体1抗体 非小细胞肺癌 淋巴细胞亚群 免疫疗法 恶性肿瘤 |
| English Keywords:Zhengyuan Capsules Programmed death receptor 1 antibody Non-small cell lung cancer Lymphocyte subsets Immunotherapy Malignant tumors |
| 基金项目:江苏省科教强卫工程项目(QNRC2016133) |
|
| 摘要点击次数: 375 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的:探讨正元胶囊联合程序性死亡受体1抗体治疗晚期非小细胞肺癌患者的有效性和安全性以及对血清中淋巴细胞亚群的影响。方法:选取2018年8月至2019年11月江阴市人民医院收治的晚期非小细胞肺癌患者48例作为研究对象，按照治疗方法不同分为对照组和观察组，每组24例。对照组采取纳武利尤单抗静脉滴注，观察组在对照组基础上同时口服正元胶囊。比较2组近期疗效、治疗过程中不良反应，检测2组患者血清中淋巴细胞亚群。结果:对照组客观缓解率高于观察组（20.83%，25.00%），疾病控制率低于观察组（54.17%，62.5%），差异均无统计学意义（P>0.05）。观察组患者的乏力、食欲下降发生少于对照组（P<0.05），2组的中性粒细胞减少、贫血、血小板减少、恶心呕吐、便秘、皮疹发生率差异无统计学意义（P>0.05）。2组患者治疗前后的总T淋巴细胞、CD4、CD8阳性细胞%和阳性细胞%差异均无统计学意义（P>0.05）。结论：正元胶囊联合程序性死亡受体1治疗非小细胞肺癌的疗效确切，安全性好，并可减少乏力、食欲下降发生率。 |
| English Summary: |
| To explore the effectiveness and safety of Zhengyuan Capsule combined with programmed death receptor 1 antibody in the treatment of patients with advanced non-small cell lung cancer and the effect on the lymphocyte subsets in serum. Methods:A total of 48 patients with non-small cell lung cancer admitted to Jiangyin People's Hospital of Jiangsu Province were selected as the research objects and were randomly divided into a control group and an observation group, with 24 cases in each group. The control group received intravenous infusion. The observation group took oral Zhengyuan Capsules on the basis of the control group. The short-term efficacy and adverse reactions during the treatment were compared between the 2 groups, and the lymphocyte subsets in the serum of the 2 groups were detected. Results:The objective response rate of the control group was higher than that of the observation group (20.83%, 25.00%), and the disease control rate was lower than that of the observation group (54.17%, 62.50%), and the difference was not significant (P>0.05). The observation group had less fatigue and decreased appetite than the control group (P<0.05). The incidence of neutropenia, anemia, thrombocytopenia, nausea and vomiting, constipation, and rash in the 2 groups was not statistically significant difference (P>0.05). There was no significant difference in the total T lymphocytes, CD4, CD8 positive cell% and negative cell% between the 2 groups of patients before and after treatment (P>0.05). Conclusion:Zhengyuan Capsule combined with programmed death receptor 1 has a definite effect on the treatment of non-small cell lung cancer, with good safety, and can reduce the incidence of fatigue and decreased appetite. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
